nach oben

International Urology and Nephrology

Erschienen in:

05.08.2019 | Urology - Review

Diagnostic role of kidney injury molecule-1 in renal cell carcinoma

verfasst von: Kevin J. Zhang, George D. Wilson, Sam Kara, Audrey Majeske, Ping L. Zhang, Jason M. Hafron

Erschienen in: International Urology and Nephrology | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Despite rapid advances in diagnostic and therapeutic medicine, renal cell carcinoma (RCC) continues to cause significant morbidity and mortality in patients. While there has been a shift towards earlier detection, approximately 16% of patients present with metastatic disease at the time of diagnosis. Kidney injury molecule-1 (KIM-1) is a glycoprotein that has been shown to be a robust and reliable biomarker of acute proximal tubular injury. As KIM-1 is mainly expressed in RCC derived from the proximal tubules, it is a reliable marker to differentiate between proximal tubular primary RCC and distal nephron primary RCC. Several studies have investigated urinary KIM-1 (uKIM-1) in RCC and demonstrated that it is a sensitive and specific marker for detecting localized RCC, as patients had markedly reduced uKIM-1 levels following nephrectomy, with uKIM-1 levels correlating with tumor size and grade. In addition, levels of KIM-1 present in plasma have also shown utility as a biomarker of RCC with levels being elevated in RCC cases at least 5 years before diagnosis. This review focuses on a progressive understanding of KIM-1 in the diagnosis of RCC using biopsies, urine, and plasma samples, and it will also provide some insight into potential roles of KIM-1 in the growth and spread of RCC.

Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34CrossRefPubMed

Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353(23):2477–2490CrossRefPubMed

Cancer Stat Facts: Kidney and Renal Pelvis Cancer. March 15, 2019, Available from: http://seer.cancer.gov/statfacts/html/kidrp.html

Pantuck AJ, Zisman A, Belldegrun AS (2001) The changing natural history of renal cell carcinoma. J Urol 166(5):1611–1623CrossRefPubMed

Kane CJ et al (2008) Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer 113(1):78–83CrossRefPubMed

Figlin RA (1999) Renal cell carcinoma: management of advanced disease. J Urol 161(2):381–386 discussion 386–7 CrossRefPubMed

Linehan JA, Nguyen MM (2009) Kidney cancer: the new landscape. Curr Opin Urol 19(2):133–137CrossRefPubMed

Ichimura T et al (1998) Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 273(7):4135–4142CrossRefPubMed

Han WK et al (2002) Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 62(1):237–244CrossRefPubMed

10.

Zhang PL et al (2008) Kidney injury molecule-1 expression in transplant biopsies is a sensitive measure of cell injury. Kidney Int 73(5):608–614CrossRefPubMed

11.

van Timmeren MM et al (2007) Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol 212(2):209–217CrossRefPubMed

12.

Yin W et al (2018) Kidney injury molecule-1 identifies antemortem injury in postmortem adult and fetal kidney. Am J Physiol Renal Physiol 315(6):F1637–F1643CrossRefPubMedPubMedCentral

13.

Ichimura T et al (2004) Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol 286(3):F552–F563CrossRefPubMed

14.

van Timmeren MM et al (2007) High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients. Transplantation 84(12):1625–1630CrossRefPubMedPubMedCentral

15.

Vaidya VS et al (2009) A rapid urine test for early detection of kidney injury. Kidney Int 76(1):108–114CrossRefPubMedPubMedCentral

16.

Zhang Z, Humphreys BD, Bonventre JV (2007) Shedding of the urinary biomarker kidney injury molecule-1 (KIM-1) is regulated by MAP kinases and juxtamembrane region. J Am Soc Nephrol 18(10):2704–2714CrossRefPubMed

17.

Vaidya VS et al (2008) Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci 1(3):200–208CrossRefPubMedPubMedCentral

18.

Sabbisetti VS et al (2013) Novel assays for detection of urinary KIM-1 in mouse models of kidney injury. Toxicol Sci 131(1):13–25CrossRefPubMed

19.

Sabbisetti VS et al (2014) Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J Am Soc Nephrol 25(10):2177–2186CrossRefPubMedPubMedCentral

20.

Ibrahim NE et al (2019) Blood kidney injury molecule-1 predicts short and longer term kidney outcomes in patients undergoing diagnostic coronary and/or peripheral angiography-Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. Am Heart J 209:36–46CrossRefPubMed

21.

Alderson HV et al (2016) The associations of blood kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin with progression from CKD to ESRD. Clin J Am Soc Nephrol 11(12):2141–2149CrossRefPubMedPubMedCentral

22.

Bailly V et al (2002) Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J Biol Chem 277(42):39739–39748CrossRefPubMed

23.

Han WK et al (2005) Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol 16(4):1126–1134CrossRefPubMed

24.

Lin F et al (2007) Human kidney injury molecule-1 (hKIM-1): a useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma. Am J Surg Pathol 31(3):371–381CrossRefPubMed

25.

Zhang PL et al (2014) Urine kidney injury molecule-1: a potential non-invasive biomarker for patients with renal cell carcinoma. Int Urol Nephrol 46(2):379–388CrossRefPubMed

26.

Ichimura T et al (2008) Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest 118(5):1657–1668CrossRefPubMedPubMedCentral

27.

Du P et al (2016) Immune regulation and antitumor effect of TIM-1. J Immunol Res 2016:8605134CrossRefPubMedPubMedCentral

28.

Ichimura T, Brooks CR, Bonventre JV (2012) Kim-1/Tim-1 and immune cells: shifting sands. Kidney Int 81(9):809–811CrossRefPubMedPubMedCentral

29.

Brooks CR et al (2015) KIM-1-/TIM-1-mediated phagocytosis links ATG5-/ULK1-dependent clearance of apoptotic cells to antigen presentation. EMBO J 34(19):2441–2464CrossRefPubMedPubMedCentral

30.

Yang L et al (2015) KIM-1-mediated phagocytosis reduces acute injury to the kidney. J Clin Invest 125(4):1620–1636CrossRefPubMedPubMedCentral

31.

Chen M, Wang J (2010) Programmed cell death of dendritic cells in immune regulation. Immunol Rev 236:11–27CrossRefPubMedPubMedCentral

32.

Henry F et al (1999) Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res 59(14):3329–3332PubMed

33.

Sanchez-Paulete AR et al (2017) Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Ann Oncol 28(suppl_12):xii74CrossRefPubMed

34.

da Silva RP, Gordon S (1999) Phagocytosis stimulates alternative glycosylation of macrosialin (mouse CD68), a macrophage-specific endosomal protein. Biochem J 338(Pt 3):687–694CrossRefPubMedPubMedCentral

35.

Holness CL, Simmons DL (1993) Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 81(6):1607–1613CrossRefPubMed

36.

de Souza AJ et al (2008) T cell Ig and mucin domain-1-mediated T cell activation requires recruitment and activation of phosphoinositide 3-kinase. J Immunol 180(10):6518–6526CrossRefPubMed

37.

Cuadros T et al (2014) HAVCR/KIM-1 activates the IL-6/STAT-3 pathway in clear cell renal cell carcinoma and determines tumor progression and patient outcome. Cancer Res 74(5):1416–1428CrossRefPubMed

38.

Xu J et al (2018) Targeted silencing of Kim-1 inhibits the growth of clear cell renal carcinoma cell line 786–0 in vitro and in vivo. Oncol Res 26(7):997–1003CrossRefPubMedPubMedCentral

39.

Thomas LJ et al (2016) Development of a novel antibody-drug conjugate for the potential treatment of ovarian, lung, and renal cell carcinoma expressing TIM-1. Mol Cancer Ther 15(12):2946–2954CrossRefPubMed

40.

Mesri M et al (2006) Inhibition of in vitro and in vivo T cell responses by recombinant human Tim-1 extracellular domain proteins. Int Immunol 18(3):473–484CrossRefPubMed

41.

Meyers JH et al (2005) TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation. Nat Immunol 6(5):455–464CrossRefPubMed

42.

Kondratowicz AS et al (2011) T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc Natl Acad Sci USA 108(20):8426–8431CrossRefPubMedPubMedCentral

43.

Curtiss M, Colgan J (2007) The role of the T-cell costimulatory molecule Tim-1 in the immune response. Immunol Res 39(1–3):52–61CrossRefPubMed

44.

Mariat C et al (2009) Tim-1 signaling substitutes for conventional signal 1 and requires costimulation to induce T cell proliferation. J Immunol 182(3):1379–1385CrossRefPubMed

45.

Sizing ID et al (2007) Epitope-dependent effect of anti-murine TIM-1 monoclonal antibodies on T cell activity and lung immune responses. J Immunol 178(4):2249–2261CrossRefPubMed

46.

Schweigert O et al (2014) Soluble T cell immunoglobulin and mucin domain (TIM)-1 and -4 generated by A Disintegrin And Metalloprotease (ADAM)-10 and -17 bind to phosphatidylserine. Biochim Biophys Acta 1843(2):275–287CrossRefPubMed

47.

Kara S et al (2019) Identification of novel susceptibility genes associated with seven autoimmune disorders using whole genome molecular interaction networks. J Autoimmun 97:48–58CrossRefPubMed

48.

Zhang PL, Hafron JM (2014) Progenitor/stem cells in renal regeneration and mass lesions. Int Urol Nephrol 46(11):2227–2236CrossRefPubMed

49.

Tickoo SK et al (2006) Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol 30(2):141–153CrossRefPubMed

50.

Aron M et al (2015) Clear cell-papillary renal cell carcinoma of the kidney not associated with end-stage renal disease: clinicopathologic correlation with expanded immunophenotypic and molecular characterization of a large cohort with emphasis on relationship with renal angiomyoadenomatous tumor. Am J Surg Pathol 39(7):873–888CrossRefPubMed

51.

Chen WJ et al (2018) Clear cell papillary renal cell carcinoma—An indolent subtype of renal tumor. J Chin Med Assoc 81(10):878–883CrossRefPubMed

52.

Zhou H et al (2014) Clear cell papillary renal cell carcinoma is the fourth most common histologic type of renal cell carcinoma in 290 consecutive nephrectomies for renal cell carcinoma. Hum Pathol 45(1):59–64CrossRefPubMed

53.

Moch H et al (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol 70(1):93–105CrossRefPubMed

54.

Srigley JR et al (2013) The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol 37(10):1469–1489CrossRefPubMed

55.

Morrissey JJ et al (2011) Sensitivity and specificity of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 for the diagnosis of renal cell carcinoma. Am J Nephrol 34(5):391–398CrossRefPubMed

56.

Mijuskovic M et al (2018) Tissue and urinary KIM-1 relate to tumor characteristics in patients with clear renal cell carcinoma. Int Urol Nephrol 50(1):63–70CrossRefPubMed

57.

Scelo G et al (2018) KIM-1 as a blood-based marker for early detection of kidney cancer: a prospective nested case-control study. Clin Cancer Res 24(22):5594–5601CrossRefPubMedPubMedCentral

58.

Kuchroo VK et al (2003) The TIM gene family: emerging roles in immunity and disease. Nat Rev Immunol 3(6):454–462CrossRefPubMed

59.

McIntire JJ, Umetsu DT, DeKruyff RH (2004) TIM-1, a novel allergy and asthma susceptibility gene. Springer Semin Immunopathol 25(3–4):335–348CrossRefPubMed

60.

Motzer RJ et al (2019) Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 380(12):1103–1115CrossRefPubMedPubMedCentral

61.

Rini BI et al (2019) Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116–1127CrossRefPubMed

Titel: Diagnostic role of kidney injury molecule-1 in renal cell carcinoma
verfasst von: Kevin J. Zhang
George D. Wilson
Sam Kara
Audrey Majeske
Ping L. Zhang
Jason M. Hafron
Publikationsdatum: 05.08.2019
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 11/2019
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-019-02231-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Diagnostic role of kidney injury molecule-1 in renal cell carcinoma

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2019

Use of mammalian target of rapamycin inhibitors in patient with autosomal dominant polycystic kidney disease: an updated meta-analysis

Positive effects of the inclusion of open-mouth pressure for elimination of blood in microscopic subinguinal varicocelectomy

Gender impact on baseline peritoneal transport properties in incident peritoneal dialysis patients

Efficacy and safety of leflunomide in IgA nephropathy: a systematic review and meta-analysis

Intravesical stent position as a predictor of quality of life in patients with indwelling ureteral stent

Ultrasound-assisted microsurgical left spermatic-inferior epigastric vein anastomosis for treating nutcracker syndrome-associated varicocele

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin